Warberg Asset Management LLC boosted its holdings in ZIVO Bioscience, Inc. (NASDAQ:ZIVOW – Get Rating) by 442.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 84,654 shares of the company's stock after buying an additional 69,034 shares during the period. Warberg Asset Management LLC's holdings in ZIVO Bioscience were worth $51,000 as of its most recent filing with the Securities and Exchange Commission.
ZIVO Bioscience Stock Performance
ZIVO Bioscience stock opened at $0.88 on Wednesday. ZIVO Bioscience, Inc. has a 1-year low of $0.23 and a 1-year high of $1.52. The firm has a 50 day simple moving average of $0.71 and a 200 day simple moving average of $0.77.
Get
ZIVO Bioscience alerts:
About ZIVO Bioscience
(Get Rating)
ZIVO Bioscience, Inc is a Michigan-based biotech/agtech company dedicated to harnessing the immune health and nutritional benefits of bioactive compounds derived from its proprietary algal cultures. The development pipeline includes natural products for use as dietary supplements and functional food ingredients, as well as innovative, biologically derived and synthesized candidates designed to deliver medicinal and pharmaceutical benefits for humans and animals, with a specific focus on modulating the immune and inflammatory response.
Further Reading
- Get a free copy of the StockNews.com research report on ZIVO Bioscience (ZIVOW)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab's First U.S. Launch Send Stock Into Stratosphere?
- Is It Time To Get Aggressive With Defense Stocks?
Want to see what other hedge funds are holding ZIVOW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ZIVO Bioscience, Inc. (NASDAQ:ZIVOW – Get Rating).
Receive News & Ratings for ZIVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
Warberg Asset Management LLC boosted its holdings in ZIVO Bioscience, Inc. (NASDAQ:ZIVOW – Get Rating) by 442.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 84,654 shares of the company's stock after buying an additional 69,034 shares during the period. Warberg Asset Management LLC's holdings in ZIVO Bioscience were worth $51,000 as of its most recent filing with the Securities and Exchange Commission.
根据Warberg Asset Management LLC向美国证券交易委员会提交的最新13F文件，华伯格资产管理有限责任公司在第三季度将其在ZIVO Bioscience, Inc.（纳斯达克股票代码：ZIVOW — Get Rating）的持股量增加了442.0％。该机构投资者在此期间又购买了69,034股股票后，拥有该公司的84,654股股票。截至最近向美国证券交易委员会提交的文件，Warberg Asset Management LLC在ZIVO Bioscience的持股价值51,000美元。
ZIVO Bioscience Stock Performance
ZIVO Bioscience stock opened at $0.88 on Wednesday. ZIVO Bioscience, Inc. has a 1-year low of $0.23 and a 1-year high of $1.52. The firm has a 50 day simple moving average of $0.71 and a 200 day simple moving average of $0.77.
ZIVO Bioscience股票周三开盘价为0.88美元。ZIVO Bioscience, Inc.创下1年低点0.23美元，1年高点为1.52美元。该公司的50天简单移动平均线为0.71美元，200天简单移动平均线为0.77美元。
Get
ZIVO Bioscience
alerts:
About ZIVO Bioscience
ZIVO Bioscience, Inc is a Michigan-based biotech/agtech company dedicated to harnessing the immune health and nutritional benefits of bioactive compounds derived from its proprietary algal cultures. The development pipeline includes natural products for use as dietary supplements and functional food ingredients, as well as innovative, biologically derived and synthesized candidates designed to deliver medicinal and pharmaceutical benefits for humans and animals, with a specific focus on modulating the immune and inflammatory response.
ZIVO Bioscience, Inc是一家总部位于密歇根州的生物技术/农业科技公司，致力于利用其专有藻类培养物衍生的生物活性化合物的免疫健康和营养益处。该开发产品包括用作膳食补充剂和功能性食品原料的天然产品，以及旨在为人类和动物提供药用和药物益处的创新、生物衍生和合成的候选产品，特别侧重于调节免疫和炎症反应。
Further Reading
- Get a free copy of the StockNews.com research report on ZIVO Bioscience (ZIVOW)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab's First U.S. Launch Send Stock Into Stratosphere?
- Is It Time To Get Aggressive With Defense Stocks?
- 免费获取 StockNews.com 关于 ZIVO Bioscience (ZIVOW) 的研究报告
- Pliant Therapeutics 的差距上涨了 34%：还有更多上行空间？
- 2023 年初的裁员将如何影响这5只生物技术股？
- 在飙升70％之后，Baudax Bio投资者的痛苦结束了吗？
- 火箭实验室在美国的首次发射会将股票送入平流层吗？
- 是时候对国防股采取积极行动了吗？
Want to see what other hedge funds are holding ZIVOW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ZIVO Bioscience, Inc. (NASDAQ:ZIVOW – Get Rating).
想看看还有哪些对冲基金持有 ZIVOW 吗？ 访问Holdingschannel.com，获取ZIVO Bioscience, Inc.（纳斯达克股票代码：ZIVOW — 获取评级）的最新13F文件和内幕交易。
Receive News & Ratings for ZIVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
接收《ZIVO 生物科学日报》的新闻和评级 -在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收ZIVO Bioscience及相关公司的最新新闻和分析师评级的简明每日摘要。
